8-K: Envoy Medical Advances Acclaim Trial, Secures CPT Codes for Esteem Amidst Rising Losses in Q2 2025

Envoy Medical reported its second quarter 2025 financial results, highlighting significant progress in its Acclaim cochlear implant clinical trial and the approval of new CPT codes for its Esteem device, despite an increase in net losses and a growing accumulated deficit.

Summary

• Successfully activated all 10 study participants in the first stage of the pivotal clinical trial for the fully implanted Acclaim cochlear implant.
• All 10 Acclaim study participants completed their one-month follow-up visits with no serious adverse events or unanticipated device events reported.
• Five Category III CPT codes for totally implantable active middle ear implants, including the Esteem device, became effective on July 1, 2025, potentially expanding market access.
• Two new patents in the US and three new patents in Australia were issued, strengthening the intellectual property portfolio.
• Net revenues increased by $10 thousand to $78 thousand for the three months ended June 30, 2025, compared to $68 thousand in the prior year period.
• Research and development (R&D) expenses decreased by $0.1 million to $2.485 million for the three months ended June 30, 2025, primarily due to a shift from development to clinical trials.
• General and administrative (G&A) expenses increased by $0.5 million for the three months ended June 30, 2025, largely due to a $0.3 million severance accrual.
• Net loss for the second quarter of 2025 increased to $5.69 million, compared to $3.95 million for the same period in 2024.
• Cash balance as of June 30, 2025, was approximately $5.3 million.
• Total liabilities increased significantly to $39.76 million as of June 30, 2025, from $30.38 million at December 31, 2024, driven by an increase in term loans payable.
• Accumulated deficit grew to $29.86 million as of June 30, 2025, from $18.84 million at December 31, 2024.

Sentiment

Score: 6

Explanation: The sentiment is mixed. Significant positive progress in clinical trials and regulatory approvals for key products (Acclaim and Esteem) provides strong long-term potential. However, this is tempered by worsening financial results, including increased net losses and a growing accumulated deficit, alongside a substantial increase in related-party debt, indicating ongoing financial challenges.

Positives

• Successful activation of all 10 study participants in the pivotal clinical trial for the Acclaim cochlear implant, indicating strong progress.
• Completion of one-month follow-up visits for all 10 Acclaim study participants with no reported serious adverse events or unanticipated device events, suggesting device safety and performance.
• Approval of five Category III CPT codes for totally implantable active middle ear implants, including the Esteem device, effective July 1, 2025, which is expected to improve market adoption and access.
• Issuance of two new US patents and three new Australian patents, strengthening the company's intellectual property portfolio.
• Net revenues increased by $10 thousand in Q2 2025 compared to Q2 2024.
• R&D expenses decreased by $0.1 million in Q2 2025, reflecting a shift from development to clinical trial phase, which can be more cost-efficient in the short term.

Negatives

• Net loss increased to $5.69 million for Q2 2025, up from $3.95 million in Q2 2024, indicating worsening profitability.
• General and administrative expenses increased by $0.5 million in Q2 2025, primarily due to a $0.3 million severance accrual.
• Cash balance decreased to $5.287 million as of June 30, 2025, from $5.483 million at December 31, 2024.
• Total liabilities significantly increased to $39.76 million as of June 30, 2025, from $30.38 million at December 31, 2024, largely due to increased term loans payable.
• Accumulated deficit grew to $29.86 million as of June 30, 2025, from $18.84 million at December 31, 2024, reflecting continued losses.

Risks

• Changes in the market price of Class A Common Stock.
• Changes in or removal of the company's shares inclusion in any index.
• Success in retaining or recruiting, or changes required in, officers, key employees, or directors.
• Unpredictability in the medical device industry, the regulatory process to approve medical devices, and the clinical development process of products.
• Competition in the medical device industry, and the failure to introduce new products and services in a timely manner or at competitive prices to compete successfully against competitors.
• Disruptions in relationships with suppliers, or disruptions in the company's own production capabilities for some of the key components and materials of its products.
• Changes in the need for capital and the availability of financing and capital to fund these needs.
• Changes in interest rates or rates of inflation.
• Legal, regulatory, and other proceedings could be costly and time-consuming to defend.
• Changes in applicable laws or regulations, or the application thereof on the company.
• A loss of any of the company's key intellectual property rights or failure to adequately protect intellectual property rights.
• The effects of catastrophic events, including war, terrorism, and other international conflicts.

Future Outlook

The company anticipates its Acclaim cochlear implant study participants will complete their three-month follow-up visits in the coming weeks. Management is confident that, once approved, the fully implanted Acclaim cochlear implant will generate substantial patient interest and disrupt the established market, allowing for rapid growth. The company believes the Acclaim CI is well-positioned to capture market share as the industry shifts towards fully implanted cochlear implants. For the Esteem device, meaningful changes to reimbursement policies are expected to provide a viable pathway for this FDA-approved, one-of-a-kind product, and the company continues to see wisdom in strategic investments around it. The company remains steadfast in its belief that it will be a significant player in the hearing device industry in the near future and continues to pursue additional patent protection globally.

Management Comments

• "This quarter was another win for Envoy Medical as we continue to successfully execute our strategy."
• "We continued to make significant strides with our clinical study as all 10 study participants in the Acclaim trial were successfully activated and completed their one-month follow-up visits with zero reported serious adverse events or unanticipated device events."
• "We are confident that, once approved, our fully implanted Acclaim cochlear implant will enjoy substantial patient interest, allowing us a rare opportunity to disrupt an established market and grow into a significant market participant relatively quickly."
• "We believe our investigational fully implanted Acclaim cochlear implant is well-positioned to be able to capture market share as the industry moves towards fully implanted cochlear implants and away from bulky externals."
• "As it relates to the Esteem fully implanted active middle ear implant, which already has FDA approval, we are excited to see the potential for renewed opportunity and possibility."
• "Meaningful changes to reimbursement around this class of hearing devices would provide Envoy Medical with a viable pathway for a product that already has FDA approval, is currently one-of-a-kind in the marketplace, and has demonstrated patient demand."
• "We continue to see wisdom in strategic investments around this product, as a shift in policy or reimbursement could rapidly change Envoy Medicals position in the market."
• "As we continue to execute our strategy and drive shareholder value, we remain steadfast in our belief that Envoy Medical will be a significant player in the hearing device industry in the near future."

Industry Context

The announcement reflects a broader trend in the hearing health industry towards more discreet and fully implanted devices, moving away from traditional external hearing aids and cochlear implant components. The approval of Category III CPT codes for fully implanted active middle ear implants is a critical development, as reimbursement codes are essential for market adoption and patient access to new medical technologies. This regulatory milestone could significantly open up the market for devices like the Esteem, which previously faced limitations due to a lack of specific coding. The company's focus on its investigational Acclaim cochlear implant also aligns with the industry's pursuit of advanced solutions for severe to profound hearing loss, aiming to disrupt the established market with a fully implanted option.

Comparison to Industry Standards

• No specific comparable companies, projects, or results are mentioned in the filing for direct comparison to industry standards.

Related Party Transactions

• Term loans payable (related party) increased to $27.932 million as of June 30, 2025, from $18.716 million at December 31, 2024.
• Accrued interest (related party) was $1.034 million as of June 30, 2025, up from $703 thousand at December 31, 2024.
• Operating lease right-of-use asset (related party) was $828 thousand as of June 30, 2025.
• Operating lease liability, current portion (related party) was $198 thousand as of June 30, 2025.
• Operating lease liability, net of current portion (related party) was $703 thousand as of June 30, 2025.
• Proceeds from the issuance of term loans payable (related party) were $10.0 million for the six months ended June 30, 2025.
• Interest expense, related party, was $624 thousand for Q2 2025 and $1.119 million for the six months ended June 30, 2025.
• Warrants issued with term loans payable (related party) amounted to $1.57 million for the six months ended June 30, 2025.

Stakeholder Impact

• Shareholders: Potential for long-term value creation from successful product development and market expansion, but current increased losses and growing deficit may cause short-term concern and share price volatility.
• Patients: Positive impact through the continued development of innovative, fully implanted hearing devices (Acclaim) and improved access to existing FDA-approved devices (Esteem) due to new CPT codes.
• Employees: A $0.3 million severance accrual indicates some personnel changes or restructuring, while additional headcount for clinical trials suggests growth in R&D.
• Creditors: Increased term loans payable and total liabilities indicate higher financial leverage and reliance on debt financing, particularly from related parties.

Next Steps

• Completion of three-month follow-up visits for the Acclaim cochlear implant study participants in the coming weeks.
• Continued pursuit of additional patent protection across the Globe.
• Potential for further changes to reimbursement policies around the Esteem device to provide additional business opportunities.

Key Dates

Recommendation

The company demonstrates significant progress in its core product development, particularly with the Acclaim cochlear implant's clinical trial and the Esteem device's market access via new CPT codes. These are strong indicators of future growth potential in the innovative hearing health sector. However, the worsening financial performance, marked by increased net losses, a growing accumulated deficit, and a substantial increase in related-party debt, presents considerable financial risk. A 'hold' recommendation is appropriate, acknowledging the promising long-term prospects while advising caution due to current financial challenges and the need for improved profitability and reduced reliance on debt before a more bullish stance can be taken.

Keywords

Hearing health, Cochlear implant, Medical device, Esteem, Acclaim, FDA, CPT codes, Clinical trial, Intellectual property, Financial results, Quarterly report